This article refers to:
Lajara R. The MARLINA-T2D trial: putting the results into clinical perspective. Expert Review of Endocrinology & Metabolism. 2018;1-4.
https://doi.org/10.1080/17446651.2018.1455497
When the above article was first published online, the permission statement ‘‘Reprinted from Groop et al. Diabetes Obes Metab 2017;19:1610-1619’’ was omitted in error from the figure 1 legend. The complete figure caption is provided below.
Figure 1. Distribution of UACR change from baseline at week 24 by UACR response categories in the full analysis set in eligible participants with a UACR value at week 24 irrespective of glycemic rescue therapy (black, linagliptin; white, placebo). Reprinted from Groop et al. Diabetes Obes Metab 2017;19:1610-1619.